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regimens of antimycobacterial drugs that are also effective 
against M. avium complex (4).
In 2 studies that evaluated the effect of adjunctive IL-2 
therapy in addition to ART for previously treatment-naive 
patients with HIV infection, baseline median numbers of 
circulating CD4+ cells increased significantly, but expan-
sion of CD4+ T cells was not associated with the reduc-
tion in the risk for opportunistic diseases or death (8). In 
contrast to these results, in a study of HIV-positive patients 
who had low circulating CD4+ T cell counts, the partici-
pants experienced fewer AIDS-defining events and fewer 
deaths occurred when they were treated with adjunctive 
IL-2 immunotherapy (9).
This case report provides lessons for the understand-
ing of mycobacterial diseases. First, despite massive in-
filtration of duodenal mucosa, mesenterial lymph nodes, 
and bone marrow, the lack of inflammatory responses in 
this patient prevented tissue destruction. Second, in the ab-
sence of a sufficient immune response and an increase in 
the number of circulating CD4+ T cells, antimycobacterial 
therapy without adjunctive immunotherapy did not clear 
the systemic bacterial infection.
Host responses to pathogens are not always beneficial. 
Intense immune reactions experienced during episodes of 
sepsis or HIV immune reconstitution inflammatory syn-
drome are frequently associated with patient death. Alter-
nately, in the absence of inflammatory responses to patho-
gens, the patient is unprotected, and even microbiota that 
are harmless to an immunocompetent person can adversely 
invade. In an optimal immune response setting, a balance 
between proinflammatory and anti-inflammatory factors in 
response to pathogens is maintained (10).
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To the Editor: Corynebacterium bovis is well known 
as a normal bovine microbiota and is a common cause of 
bovine mastitis (1). C. bovis infections in humans are rare, 
and identification of the organism by biochemical meth-
ods is challenging (2). Although 9 cases of C. bovis infec-
tions in humans have been reported (3–6), only the most 
recent case, which involved prosthetic joint infection, 
used 16S rRNA gene sequencing to identify the bacterium 
with certainty (6).
During February–July 2013, four adult patients (Ta-
ble) were seen at Veterans Administration Puget Sound 
Health Care System in Seattle, Washington, USA, for eye 
swelling, pain, and purulent discharge. All 4 cases were 
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associated with isolation of C. bovis from essentially pure 
culture. We investigated these 4 cases after obtaining ap-
proval from the Puget Sound Veterans Administration Med-
ical Center Institutional Review Board (MIRB #01012).
Patient 1 was a 49-year-old man with swelling of the 
right eyelid with discharge and pain after an episode of 
itching. Before this visit, the patient had 3 similar episodes 
and received incision and drainage of the eyelid. On exami-
nation, the inverted lower palpebrum revealed a purulent 
cyst (diameter 1–2 mm); pus was collected from the cyst 
for culture. The patient was prescribed tobramycin ophthal-
mic drops and amoxicillin/clavulanic acid. No follow-up 
information was available.
Patient 2 was a 25-year-old man with bilateral eye in-
fection that started on the left eye a week before the pa-
tient sought care. The eye had redness, swelling, blurred 
vision with loss of acuity, and irritation. The right eye had 
the same symptoms on the day of visit. Examination found 
bilateral keratoconjunctivitis and a 3-mm cyst with drain-
age on the lower palpebrum. The patient was treated with 
ofloxacin ophthalmic drops for 4 months but did not im-
prove. A specimen was then collected from his right eye 
for culture. In 2014, he was given a diagnosis of chronic 
conjunctivitis.
Patient 3 was a 33-year-old man with severe pain, 
erythema, and swelling on his left eyelid. His symptoms 
started 1 week before he sought care and included swell-
ing, increased cyst size, and disturbed vision. The pustular 
exudate was aspirated and sent to the laboratory. The pa-
tient was prescribed erythromycin ointment and oral trime-
thoprim/sulfamethoxazole. The patient’s eye had improved 
at 3 weeks.
Patient 4 was a 90-year-old man who fell at home 2 
days before his visit. He landed on his cheek, causing an 
abrasion, and his eye was swollen shut a few hours after 
the fall. On the second day, his cheek was swollen and red-
dened, and yellowish purulent matter was present on the 
skin. A swab specimen was collected from the wound and 
sent for culture. The patient was treated with doxycycline 
for 14 days, and the wound healed by day 12.
The aerobic cultures of 3 eye and 1 cheek wound 
specimens from these patients grew gram-positive bacilli 
(Table). The organism was initially identified by the API 
Coryne system (biomérieux, Marcy l’Etoile, France) as 
C. urealyticum or Corynebacterium group F-1. However, 
given the difficulty of phenotypic identification and the 
lack of literature to support eye infections associated with 
C. urealyticum, we performed 16S rRNA gene sequence 
analysis of the first ≈500 bp to confirm the identity. Using 
the MicroSeq 500 database version 0023b (Applied Bio-
systems, Foster City, CA, USA), we identified all 4 isolates 






















F7181 F7545 F7275 F7551 
Patient	no. 1 2 3 4     
Age,	y/sex 49/M 25/M 33/M 90/M     









Bellevue	clinic     
API	Coryne	test	code 2001004 0001004 0001105 0001004     
Test	results         
 Production	of         
  Catalase + + + +  + 100 100 
  Urease + + + +  – 44–68 17 
  Pyrazinamidase + – – –  + ND ND 
 Acid	production	from         
  Glucose – – + –  + 56–98 50 
  Galactose – – – –  + 11–31 33 
  Mannose – – – –  + 5–33 33 
  Lactose – – – –  + 11–26 17 
  Sucrose – – + –  ND ND ND 




100 100 100 100     
Length	of	16S rRNA	gene	
sequence,	nt 
465 424 465 436     
*Phenotypic	characteristics	of	C. bovis isolates	from	this	study	(2)	were	obtained	by	using	API	Coryne	system	v3.0	and	Vitek2	(bioMérieux,	Marcy	 
l’Etoile, France). +, positive; –,	negative;	ED,	emergency	department;	ND,	not	determined;	VAPSHCS,	Veterans	Administration	Puget	Sound	Health	 
Care	System. 
†% strains positive. 
 
424–465 nt). According to the MicroSeq 500 and GenBank 
databases, the next 2 closest matches were C. confusum 
(96.1% similarity) and C. macginleyi (95.9% similarity), 
making the identification unambiguous.
C. bovis has not been described as part of the human 
microbiota, nor has it been associated with eye infections, 
in contrast to other Corynebacterium spp. known to colo-
nize the human conjunctiva and skin (7) and cause eye in-
fections (8,9). We found C. bovis associated with each of 
these eye and facial soft-tissue infections, but whether this 
lipophilic organism colonizes in the oily glands of eyelids 
in healthy individuals is unclear. What is certain is that C. 
bovis can exist on the human facial skin, has pathogenic 
potential, and is difficult to identify.
Because human and animal strains of C. bovis vary in 
biochemical properties (2), phenotypic identification is un-
reliable. All our isolates were urease positive, contrary to 
most isolates reported in the literature (2). This phenotype 
may result in underreporting of the organism because it is not 
described in some databases (10). An epidemiologic investi-
gation revealed no overlap among any of the specimens re-
garding date of collection, clinic location where patients were 
seen, or date of clinical work-up. From results of our investi-
gation, we believe that cross-contamination was unlikely and 
that these cases are probably independent of each other.
The pathogenicity of Corynebacterium spp. can be 
easily overlooked, especially because some species are 
common skin colonizers. Speciation should be prompted 
when Corynebacterium spp. are isolated in large quantity 
or from a pure culture. Unexpected phenotypic identifica-
tions such as C. urealyticum from eye specimens should be 
confirmed with 16S rRNA gene sequencing.
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